

IN THE CLAIMS:

Applicants, pursuant to revised 37 C.F.R. § 1.121, submit the following amendments to the claims:

1. (Previously amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, and a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least  $10^8$  M<sup>-1</sup>, and provided that the isolated polypeptide neither comprises SEQ ID NO:11, nor a fragment thereof of about 50 to 79 contiguous residues in length.

2. (Previously amended) The isolated polypeptide of claim 1, wherein the isolated polypeptide is from about 69 to 79 contiguous residues in length.

3. (Previously amended) The isolated polypeptide of claim 1, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, and provided that the isolated polypeptide does not comprise SEQ ID NO:11.

4-7 (Cancelled).

8. (Previously amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, and a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least  $10^8$  M<sup>-1</sup>, and provided that the isolated polypeptide neither comprises SEQ ID NO:12, nor a fragment thereof of about 80 to 419 contiguous residues in length.

9. (Currently amended) The isolated ~~and~~ polypeptide of claim 8, wherein the isolated polypeptide is from about 350 to 419 contiguous residues in length and at least three N-linked glycosylation sites are present.

10. (Previously amended) The isolated polypeptide of claim 8, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, and provided that the isolated polypeptide does not comprise SEQ ID NO:12.

11-17 (Cancelled).

18. (Currently amended) A pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of: (a) an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, and a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least  $10^8$  M<sup>-1</sup>, and provided that the isolated polypeptide neither comprises SEQ ID NO:11, nor a fragment thereof of about 50 to 79 contiguous residues in length; (b) an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, and a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length, wherein the C terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least  $10^8$  M<sup>-1</sup>, and provided that the isolated polypeptide neither comprises SEQ ID NO:12, nor a fragment thereof of about 80 to 419 contiguous residues in length; (c) a monoclonal antibody that binds to the extracellular domain (ECD) of HER-2; and (d) combinations thereof, and a pharmaceutically acceptable carrier, with the proviso that where the composition comprises the monoclonal antibody it also comprises at least one of the agents of (a) or (b) provided that the agent cannot be the monoclonal antibody alone, and a pharmaceutically acceptable carrier.

19. (Previously amended) The pharmaceutical composition of claim 18, wherein the agent is the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, and a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length, and provided that the isolated polypeptide neither comprises SEQ ID NO:11, nor a fragment thereof of about 50 to 79 contiguous residues in length.

20. (Previously amended) The pharmaceutical composition of claim 18, wherein the agent is the combination of the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, and a fragment of SEQ ID NO:1 of about 50 to 79 contiguous residues in length, and the monoclonal antibody that binds to the extracellular domain

(ECD) of HER-2, and provided that the isolated polypeptide neither comprises SEQ ID NO:11, nor a fragment thereof of about 50 to 79 contiguous residues in length.

21-37 (Cancelled).

38. (Previously added) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1, provided that the isolated polypeptide does not consist of SEQ ID NO:11.

39. (Previously added) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:2, provided that the isolated polypeptide does not consist of SEQ ID NO:12.

40. (Previously added) The pharmaceutical composition of claim 18, wherein the agent is the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, and a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length, and provided that the isolated polypeptide neither comprises SEQ ID NO:12, nor a fragment thereof of about 80 to 419 contiguous residues in length.

41. (Previously added) The pharmaceutical composition of claim 18, wherein the agent is the combination of the isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2 and a fragment of SEQ ID NO:2 of about 80 to 419 contiguous residues in length, and the monoclonal antibody that binds to the extracellular domain (ECD) of HER-2, and provided that the isolated polypeptide neither comprises SEQ ID NO:12, nor a fragment thereof of about 80 to 419 contiguous residues in length.

42. (New) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:14, and a fragment of SEQ ID NO:14 of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least  $10^8 \text{ M}^{-1}$ .

43. (New) The isolated polypeptide of claim 42, wherein the isolated polypeptide is from about 69 to 79 contiguous residues in length.

44. (New) The isolated polypeptide of claim 42, wherein the isolated polypeptide comprises SEQ ID NO:14.

45. (New) An isolated polypeptide consisting of SEQ ID NO:14.

46. (New) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:15, and a fragment of SEQ ID NO:15 of about 80 to 419 contiguous residues in length, wherein the C-terminal 79 contiguous amino acids are present, wherein at least one N-linked glycosylation site is present, and wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity binding constant of at least  $10^8$  M<sup>-1</sup>.

47. (New) The isolated polypeptide of claim 46, wherein the isolated polypeptide is from about 350 to 419 contiguous residues in length and at least three N-linked glycosylation sites are present.

48. (New) The isolated polypeptide of claim 46 wherein the isolated polypeptide comprises SEQ ID NO:15.

49. (New) An isolated polypeptide consisting of SEQ ID NO:15.